BELIMUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: OUTCOMES IN ROUTINE CLINICAL PRACTICE
C. Marián1, M. Garjo1, C. Itilguer2, E. Díez2, C. Díez2, L. Gómez-Lechón2, J. Martín2, M. Corteguera2, O. Martínez2, J. Cabezás2, T. Pérez2, 1Hospital León, León; 2Hospital El Bierzo, Ponferrada; 3Hospital Salamanca, Salamanca; 4Hospital Rio Hortega, Valladolid; 5Hospital Ávila, Ávila; 6Hospital Zamora, Zamora, Spain

Background: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with a wide range of clinical manifestations. The persistence of activity of the disease and the prolonged use of corticosteroids are among the main predictors of accumulated organ damage in patients with SLE. Therefore, we need new strategies to induce long-lasting remission and minimise the adverse effects of standard medications.

Objectives: to assess the effectiveness and safety of Belimumab in clinical practice during the first year of treatment in patients with SLE.

Methods: retrospective observational study of patients treated with Belimumab. This study involves 6 hospitals in Castilla y León (Spain). It collects clinical and analytical data before the start of Belimumab, and 6 and 12 months after the initiation of the therapy. The data collected include the daily dose of prednisone received at different time points and the activity of the disease was classified as mild, moderate and severe based on SELENA-SLEDAI index. A reduction from baseline of 3 points on the SELENA-SLEDAI index means significant symptomatic improvement.

Results: Among the twenty-five patients were included, with a mean age of 43.7 ±12.2 years, 72% were female and 96% Caucasian. The average time from diag- nosis of SLE to Belimumab infusion was 9.5–7.1 years; 32% were diagnosed with SLE <5 years ago. Up to 56% of the patients had moderate disease activity and only 8% patients had very high activity of the disease. All but one of the patients had previously received an immunosuppressant (azathioprine in 50% of the cases) and 16% of the sample had not responded to rituximab. The most frequent reasons for initiating Belimumab were an ineffective previous treatment regimen (60%), the intent to decrease steroid use (58%), and worsening patient condition (52%); whereas the most frequent manifestation of SLE in these patients were arthritis (44%), followed by mucocutaneous (20%) and immunologic findings (20%). As for immunologic markers of activity, DNA was elevated by 40% and 68% of the patients showed hypocomplementemia, that dropped to 24% in both cases at 12 months. The mean score of the SELENA-SLEDAI index decreased from 5.0 ± 3.0 at baseline to 3.0 ± 2.5 at 6 months and to 2.3 ± 2.3 at 12 months of follow-up. A reduc tion in the initial mean steroid dose was also observed from 20 mg/day to 8.9 mg/ day and 6.4 mg/day at 6 and 12 months respectively. Hence, the dose of steroid was reduced by 68% during the first year (p<0.06). This reduction was clinically significant, but it did not reach statistical significance in our study. Two patients (8%) had discontinued Belimumab within the first 6 months of therapy (1 pregnancy and 1 worsening proteinuria); 54.7% had discontinued it within the first 12 months, mostly due to ineffectiveness (62.5%). Two patients with severe renal involvement (>1 gr proteinuria/24 hour) were treated with Belimumab, allowing to reduce the steroids to a low dose (<7.5 mg/day) at 12 months.

Conclusions: Belimumab appears to be effective, reducing disease activity as measured by the SELENA-SLEDAI Index and, also, the mean dose of steroids needed overall, mainly after 12 months of treatment. No significant adverse effects were reported as previous studies have shown.

Disclosure of Interest: None declared

FIXED, LOW-DOSE HYDROXYCHLOROQUINE VERSUS WEIGHT-ADJUSTED DOSE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH LOW ACTIVITY
J.L. Callejas-Rubio1, D. Sanchez-Cang2, R. Ríos-Fernández2, M. Moreno-Higuera2, G. Fatou del Pro1, S. Velasco-Fuentes1, M. Trigo-Rodríguez1, N. Faro-Minguez1, 1Unidad de Enfermedades Autoinmunes Sistémicas; 2Servicio de Medicina Interna, Hospital Campus de la Salud, Granada, Spain

Background: Optimal hydroxychloroquine (HCQ) dose to reduce ocular toxicity risk is 5 mg/kg or actual weight daily, according to new recommendations. In systemic lupus erythematosus patients (SLE) with low or no disease activity, fixed low-dose HCQ might be equally effective in relapse prevention weight-adjusted doses, thus resulting in lower cumulative dose.

Objectives: Our aim was to compare a fixed dose of HCQ 200 mg daily with a weight-adjusted dose (5 mg/kg of actual weight daily) in SLE patients with low activity.

Methods: SLE activity was assessed using the SLE Disease Activity Index (SLEDAI-2K), the Safety of Oestrogen in Lupus Erythematosus National Assessment (SELENA)-SLEDAI and the Physician Global Assessment (PGA, 0–3 scale) in each visit. Low-activity SLE (LLDAS) was defined according to Franklyn et al.: 1) a SLEDAI-2K score ≤4, 2) no new SLE-related activity events compared with the previous visit, 3) a PGA score ≤1, 4) prednisone dose ≤7.5 mg daily and 5) stable doses of maintenance immunosuppressant therapy. LLDAS was evaluated at baseline and months 3 and 6. In order to adjust doses to weight, and given the impossibility of fractioning HCQ tablets, the adjusted dose was calculated for every week. For example, for 62 kg patient, the calculated dose would be 5 mgx52 kg=260 mg daily, which would mean 1820 mg weekly. Therefore, the patient would receive 400 mg daily for 2 days and 200 mg daily for 5 days every week. A relapse was defined as an increase of SLEDAI scores ≥3, according to current recommendations.

Results: A total of 59 LLDAS patients were compared, 25 with a fixed dose and 25 with a weight-adjusted dose. No significant differences regarding body weight between groups were observed: 52 kg (41.5–85.5 kg) vs. 51 kg (44–55 kg). Baseline activity scale scores were not significantly different. No patient relapsed on follow-up in either of both groups. Finally, the mean HCQ cumulative dose at 6 months was reduced by approximately 9.6 grams.

Conclusions: In LLDAS patients, a fixed HCQ dose of 200 mg daily may be as effective as the weight-adjusted dose in preventing disease relapses, thus resulting in a decrease in the HCQ cumulative dose and, therefore, a reduction of the risk of ocular toxicity.

REFERENCE:

Disclosure of Interest: None declared

KZR-616, A SELECTIVE INHIBITOR OF THE IMMUNOPROTEASOME, SHOWS A PROMISING SAFETY AND TARGET INHIBITION PROFILE IN A PHASE I, DOUBLE-BLIND, SINGLE (SAD) AND MULTIPLE ASCENDING DOSE (MAD) STUDY IN HEALTHY VOLUNTEERS
J. Lickliter1, D. Bomba2, J. Andere1, A. Fani3, C.J. Kirk2, J. Wang2, 1Nucleus Network, Melbourne, Victoria, Australia; 2Kezar Life Sciences, South San Francisco, California, USA

Background: Proteasome inhibition is a standard of care for plasma cell malignancies. Bortezomib targets the constitutive proteasome and immunoprotease, and is effective in the treatment of Systemic Lupus Erythematosus (SLE) and lupus nephritis (LN), but is associated with hematologic (e.g. thrombocytopenia) and constitutional (e.g. peripheral neuropathy) adverse events (AEs).

Objectives: We report the safety, pharmacokinetics (PK), pharmacodynamics (PD) and immunomodulatory effects of KZR-616, a first-in-class selective inhibitor of the immunoproteasome, in healthy volunteers (HV) following single and repeat subcutaneous (SC) administration.

Methods: Cohorts (6 drug:2 placebo) received single or 4 weekly SC doses. Safety assessments, PK and PD were measured to Day 7 (SAD) or Day 28 (MAD). SAD cohorts included 7.5, 15, 30 and 60 mg SC. MAD cohorts included 30, 60, and 120 mg SC and 2 intrasubject escalation cohorts with 1 dose at 30 mg and 3 doses at 45 mg. PK was measured by LCMS2. PD was measured using enzymatic and active site binding assays. Inflammatory cytokine release was measured following ex vivo stimulation of whole blood in HV receiving placebo or 45 mg KZR-616.

Results: 32 HV (24) were enrolled in 4 SAD cohorts. The most common AEs were injection site reactions (ISRs), which were generally mild and transient. No clinically-significant (CS) laboratory or ECG abnormalities and no dose limiting toxicities were observed in the SAD subjects. Following SC administration, drug exposure increased dose proportionally and was characterised by rapid absorption (Tmax15–30 min) and clearance (T1/2 ~2 hours). Inhibition of the immunoprotease exceeded 80% at >30 mg with significant recovery noted over 7 days. Constitutive proteasome inhibition was <37% in all cohorts. 40 HV (30:10) were enrolled in 5 SC MAD cohorts. In the initial cohort of 60 mg, a systemic drug reaction (chills, elevated heart rate, nausea) occurred ~8 hours after the first dose in 4 subjects. Dosing for this cohort was stopped. Subsequent cohorts (initiated at 30 mg) received prophylactic treatment with antihistamines and prednisone 30 minutes prior to the first and second dose. No similar AEs occurred with repeat dosing of 45 mg. No CS laboratory or ECG abnormalities were seen in the remaining MAD cohorts. ISRs did not appear to increase in severity or frequency with repeat dosing. There were no AEs of peripheral neuropathy, and 45 mg was well tolerated across 3 cohorts.

Disclosure of Interest: None declared

Downloaded on 12 June 2018, from http://ard.bmj.com/ on January 6, 2021 by guest. Protected by copyright.